SCHEMBL23030173

SCHEMBL23030173

CC1=CS(=O)(=O)c2ccc(Br)cc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.45
CA2 P00918 4/20 0.45
CA9 Q16790 3/20 0.45
S100A4 P26447 1/20 0.38
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RIPK2 O43353 1/20 0.33
PTPRC P08575 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
CA4 P22748 2/20 0.32
CA7 P43166 2/20 0.32
BCL2 P10415 1/20 0.32
MCL1 Q07820 1/20 0.32
CTSL P07711 1/20 0.32
CA12 O43570 1/20 0.32
TGM2 P21980 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31009700 1.00 CA1 (0.45) CA1CA2CA9S100A4LMNA
SCHEMBL23029879 0.80 CA1 (0.47) CA1CA2CA9LMNATP53
SCHEMBL3156911 0.80 S100A4 (0.40) CA1CA2CA9S100A4LMNA
SCHEMBL22058626 0.77 CYP1A2 (0.47) CA1CA2CA9S100A4LMNA
SCHEMBL24858401 0.74 NPC1 (0.44) CA1CA2CA9LMNATP53
SCHEMBL31009842 0.71 CA2 (0.50) CA1CA2CA9LMNATP53
SCHEMBL18805433 0.71 CA1 (0.50) CA1CA2CA9LMNATP53
SCHEMBL1798819 0.70 S100A4 (0.46) CA1CA2CA9S100A4PTPRC
SCHEMBL29697204 0.70 S100A4 (0.46) CA1CA2CA9S100A4PTPRC
SCHEMBL25285451 0.68 S100A4 (0.40) CA1CA2CA9S100A4PTPRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002414-A1 AZAHETEROARYL COMPOUND AND APPLICATION THEREOF SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) 2023-01-05 US disclosed
EP-4019521-A1 AZAHETEROARYL COMPOUND AND APPLICATION THEREOF Blueray Therapeutics (Shanghai) Co., Ltd (CN) 2022-06-29 EP disclosed
WO-2021032004-A9 AZAHETEROARYL COMPOUND AND APPLICATION THEREOF 上海青煜医药科技有限公司 2021-03-25 WO disclosed
WO-2021032004-A1 AZAHETEROARYL COMPOUND AND APPLICATION THEREOF 上海青煜医药科技有限公司 2021-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002414-A1 AZAHETEROARYL COMPOUND AND APPLICATION THEREOF EZH2, EED, SUZ12 CA1 2887/4885CA2 3791/4885CA9 3487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.